Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Lucentis; Belgium: Lucentis; Bulgaria: Lucentis; Cyprus: Lucentis; Czech Republic: Lucentis; Denmark: Lucentis; Estonia: Lucentis; Finland: Lucentis; France: Lucentis; Germany: Lucentis; Greece: Lucentis; Hungary: Lucentis; Ireland: Lucentis; Italy: Lucentis; Latvia: Lucentis; Lithuania: Lucentis; Luxembourg: Lucentis; Netherlands: Lucentis; Poland: Lucentis; Portugal: Lucentis; Romania: Lucentis; Slovakia: Lucentis; Slovenia: Lucentis; Spain: Lucentis; Sweden: Lucentis; UK: Lucentis.

North America

Canada: Lucentis; USA: Lucentis.

Latin America

Argentina: Lucentis.

Drug combinations


Ranibizumab: C~2158~H~3282~N~562~O~681~S~12~. Mw: approx. 48000.01. Immunoglobulin G~1~, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 γ~1~-chain), disulfide with human-mouse monoclonal rhuFAB V2 light chain. CAS-347396-82-1 (2002).

Pharmacologic Category

EENT Drugs, Miscellaneous. Angiogenesis Inhibitor. Monoclonal Antibody. Ophthalmic Agent. Vascular Endothelial Growth Factor (VEGF) Inhibitor. (ATC-Code: S01LA04).

Mechanism of action

A recombinant humanized monoclonal antibody fragment which binds to and inhibits human vascular endothelial growth factor A (VEGF-A). Ranibizumab inhibits VEGF from binding to its receptors and thereby suppressing neovascularization and slowing vision loss.

Therapeutic use

Treatment of neovascular (wet) age-related macular degeneration.

Pregnancy and lactiation implications

Use during pregnancy only if clearly needed. Excretion in breast milk unknown (use with caution in nursing women).

Unlabeled use


Hypersensitivity to ranibizumab or any component of the formulation. Ocular or periocular infection. Active intraocular inflammation.

Warnings and precautions

Intravitreous injections may be associated with endophthalmitis and retinal detachments. Hypersensitivity may present as severe intraocular inflammation. Rare hypersensitivity reactions (including anaphylaxis) associated with another VEGF inhibitor, pegaptanib, occurring within several hours of use. Following intravitreal injection, intraocular pressure may increase. Risk of thromboembolic events, particularly stroke, may be increased following intravitreal administration of VEGF inhibitors. Intravitreal injections of ranibizumab may induce temporary visual disturbances.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart